A Phase 3 interventional study of fixed dose combination of telmisartan+amlodipine and amlodipine in Hypertension, sponsored by Boehringer Ingelheim. Completed at 97 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-13.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 26th largest by enrollment of the 186 interventional ones that give a count, is one of 17 that started in 2007, is one of 69 in phase 3, and was the 49th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 947 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
122 studies in Hypertension by Boehringer Ingelheim: 1 open now, 1 under way, 1 of them phase 3. Of 120 finished, 41 (34%) have results posted.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 13th largest by enrollment of the 74 interventional ones that give a count, is one of 7 that started in 2007, is one of 43 in phase 3, and was the 29th registered.
Boehringer Ingelheim’s Hypertension studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Boehringer Ingelheim’s 122 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40mg + amlodipine 10mg (T40/A10) or the fixed dose combination of telmisartan 80mg + amlodipine 10mg (T80/A10) is superior in reducing blood pressure at eight weeks compared with amlodipine 10mg monotherapy (A10) in patients who fail to respond to six weeks treatment with A10.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change From Baseline in Trough Seated Diastolic Blood Pressure
Change from baseline to the end of study in trough DBP
Time frame: Baseline and end of study (8 weeks or last value on treatment)
Change From Baseline in Trough Seated Systolic Blood Pressure
Change from baseline to the end of study in trough SBP
Time frame: Baseline and end of study (8 weeks or last value on treatment)
Trough Seated Diastolic Blood Pressure Control (Defined as < 90mmHg)
The number of patients who reach the target DBP of \<90mmHg
Time frame: End of study (8 weeks or last value on treatment)
Trough Seated Diastolic Blood Pressure <80 mmHg
The number of patients who reach the target DBP of \<80mmHg
Time frame: End of study (8 weeks or last value on treatment)
Trough Seated DBP Response
The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg
Time frame: End of study (8 weeks or last value on treatment)
Trough Seated SBP Control
The number of patients who reach the target SBP of \<140mmHg
Time frame: End of study (8 weeks or last value on treatment)
Trough Seated SBP Response
The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg
Time frame: End of study (8 weeks or last value on treatment)
Trough Seated BP Normality Classes
The number of patients who reach predefined BP categories
Time frame: End of study (8 weeks or last value on treatment)
Oedema Incidence Rate
The number of patients who experienced at least one case of oedema or worsening of oedema for the first time (expressed as number of patients/100 patient-years)
Time frame: During randomised treatment period
Peripheral Oedema Incidence Rate
The number of cases of peripheral oedema (expressed as number of cases/100 patient-years)
Time frame: During randomised treatment period
| Milestone | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Started | 315 | 315 | 317 |
| Completed | 301 | 297 | 307 |
| Not completed | 14 | 18 | 10 |
| Withdrew: Adverse event | 8 | 10 | 5 |
| Withdrew: Non compliant with protocol | 3 | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Consent withdrawn | 2 | 3 | 1 |
| Withdrew: Specified category | 1 | 2 | 1 |
Change from baseline to the end of study in trough DBP
| mmHg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Diastolic Blood Pressure | -6.48 ± 0.45 | -9.24 ± 0.45 | -9.33 ± 0.45 |
Change from baseline to the end of study in trough SBP
| mmHg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Change From Baseline in Trough Seated Systolic Blood Pressure | -7.44 ± 0.66 | -11.09 ± 0.66 | -11.29 ± 0.66 |
The number of patients who reach the target DBP of \<90mmHg
| Participants | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Yes (DBP<90 mmHg) | 156 | 195 | 206 |
| No (DBP>=90 mmHg) | 149 | 111 | 104 |
The number of patients who reach the target DBP of \<80mmHg
| Participants | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Yes (DBP<80 mmHg) | 18 | 39 | 39 |
| No (DBP>=80 mmHg) | 287 | 267 | 271 |
The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg
| Participants | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Yes (Responder) | 163 | 202 | 213 |
| No (Non-responder) | 142 | 104 | 97 |
The number of patients who reach the target SBP of \<140mmHg
| Participants | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Yes (SBP<140 mmHg) | 153 | 180 | 187 |
| No (SBP>=140 mmHg) | 152 | 126 | 123 |
The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg
| Participants | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Yes (Responder) | 165 | 198 | 204 |
| No (Non-responder) | 140 | 108 | 106 |
The number of patients who reach predefined BP categories
| Participants | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Optimal (SBP<120 and DBP<80 mmHg) | 0 | 12 | 6 |
| Normal (SBP<130 and DBP<85 mmHg and not optimal) | 36 | 43 | 50 |
| High-normal (SBP<140 DBP<90 mmHg and not normal) | 77 | 91 | 106 |
| Stage 1 hypertension (SBP<160 and DBP<100 mmHg) | 157 | 139 | 133 |
| Stage 2 hypertension (SBP>=160 and DBP>=100 mmHg) | 35 | 21 | 15 |
The number of patients who experienced at least one case of oedema or worsening of oedema for the first time (expressed as number of patients/100 patient-years)
| Number of patients/100 patient-years | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Oedema Incidence Rate | 44.7 | 42.8 | 54.0 |
The number of cases of peripheral oedema (expressed as number of cases/100 patient-years)
| Number of cases/100 patient-years | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Peripheral Oedema Incidence Rate | 48.8 | 44.8 | 54.0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amlodipine 10mg | — | — | — |
| Telmisartan 40mg and Amlodipine 10mg | — | — | — |
| Telmisartan 80mg and Amlodipine 10mg | — | — | — |
| Event | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Cardiac failureCardiac disorders | 0/315 | 1/315 | 0/317 |
| Local swellingGeneral disorders | 0/315 | 1/315 | 0/317 |
| BronchitisInfections and infestations | 1/315 | 0/315 | 0/317 |
| Ruptured cerebral aneurysmNervous system disorders | 0/315 | 1/315 | 0/317 |
| Event | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg |
|---|---|---|---|
| Peripheral oedemaGeneral disorders | 22/315 | 21/315 | 27/317 |
| Age, Continuous(Years) | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg | Total |
|---|---|---|---|---|
| Mean | 56.4 ± 10.4 | 57.6 ± 9.4 | 55.5 ± 9.8 | 56.5 ± 9.9 |
| Sex: Female, Male(Participants) | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 10mg | Telmisartan 80mg and Amlodipine 10mg | Total |
|---|---|---|---|---|
| Female | 128 | 145 | 146 | 419 |
| Male | 187 | 170 | 171 | 528 |
The record gives a start of Nov 2007 and a primary completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlodipine